National Cancer Institute, NIH, Frederick, Maryland, USA
Dr. Dimitrov and his research group are experts in display/screening/libraries methodologies, antibody engineering, and protein biochemistry, structural biology and computational biology as well as virology, immunology and cancer biology. His major long-term goal is the development of clinically useful therapeutics and vaccines against cancer, HIV-1 and emerging and biodefense-related viruses as well as other related diseases including immune disorders. The biological therapeutics and vaccines are based on human monoclonal antibodies in several formats including full size antibodies typically IgG1s, engineered antibody domains (eAds), chimeric antigen receptors (CARs), bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), bi-specific T-cell engagers (BiTEs) and bi-specific killer-cell engagers (BiKEs).
HIV vaccines; Paradigms; Reverse vaccinology; Antibody maturation; Immunogenicity; Tat vaccine; Research funding
Journal of AIDS & Clinical Research received 5264 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 